Krsnaa Diagnostics Limited — Board/Management Information 2026

Feb 22, 2026

Date: February 22, 2026 Ref. No.: KDL/SE/105/2025-26

To, BSE Limited Corporate Relationship Department 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 Scrip Code:543328	To, National Stock Exchange of India Limited Exchange Plaza, Plot No. C-1, Block G, Bandra Kurla Complex, Bandra (East) Mumbai – 400051 NSE Symbol:KRSNAA

Subject: Disclosure under Reg. 30 read with Sch. III. Part A. Para A. Of SEBI (Listing Obligations and - Disclosure Requirements) Regulations, 2015 Outcome of Board Meeting.

The Board of Directors has, based on the recommendations of the Nomination and Remuneration Committee, and in accordance with the applicable provisions of the Companies Act, 2013, SEBI (LODR) Regulations, 2015, as well as other applicable regulatory provisions, and subject to the approval of the shareholders’ through postal ballot, accorded its approval for the re-appointment of Mr. Rajendra Mutha (DIN: 01066737), Whole-time Director and Chairman, designed as Executive Chairman, for a term of five (5) consecutive years, with effect from April 26, 2026;

The meeting commenced at 18:30 Hrs. (IST) and concluded at 21:10 Hrs. (IST).

Details required as per the relevant SEBI Circular(s) are enclosed herewith as Annexure.

It is requested to take the same on your records

Thanking you,

Yours sincerely,

For Krsnaa Diagnostics Limited

==> picture [595 x 294] intentionally omitted <==

----- Start of picture text -----

Digitally signed
Sujoy by Sujoy
Sudipta Bose
Date:
Sudipt 2026.02.22
a Bose 21:23:39 +05'30'
Sujoy Sudipta Bose
Company Secretary and Compliance Officer
----- End of picture text -----

Annexure

					Annexure
	Sr. No.		Particulars		Mr. Rajendra KhivrajMutha (DIN: 01066737)
	1.		Reason for change viz.~~appointment,~~ re-appointment,~~resignation, removal,~~ ~~death or otherwise;~~		Re-appointment of Mr. Mutha as Whole-time Director and Chairman, designated as Executive Chairman, liable to retire by rotation, for a further consecutive term of five(5) years.
	2.		Date of ~~appointment/~~re- appointment~~/cessation (as applicable)~~ ~~&~~ ~~term~~ ~~of~~ ~~appointment/re-~~ ~~appointment~~;		For a period of 5 (Five) consecutive years with effect from April 26, 2026, to April 25, 2031.
	3.		Brief profile (in case of appointment);		Mr. Mutha, the Chairman and Whole-time Director of the Company, brings over two decades of expertise in pharmacy and diagnostics. He is a certified Pharmacist accredited by the Maharashtra State Pharmacy Council, leveraging his extensive knowledge to drive the Company’s strategic vision and operational excellence. Beyond operations, he spearheads impactful outreach initiatives focused on community health, women, and children—earning recognition as a changemaker in Indian healthcare. He also leads the Company’s Corporate Social Responsibility (CSR) programmes, championing initiatives that uplift underserved communities and reinforce the Company’s role as a trusted healthcare partner.
	4.		Disclosure of relationships between directors (in case of appointment of a director).		He is not related to any of the Directors on the Board of the Company.
	5.		Confirmation in compliance with SEBI Letter dated June 14, 2018 read along with Exchange Circular dated June 20, 2018 (Affirmation that the person proposed to be appointed as Director is not debarred from holding the office by virtue of any SEBI Order or any other authority)		He is not debarred from holding the office of Director by any SEBI order or any other such authority.